Xeris Biopharma Holdings (XERS) Total Non-Current Liabilities (2020 - 2026)

Xeris Biopharma Holdings' Total Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $370.9 million for Q1 2026.

• Quarterly Total Non-Current Liabilities rose 7.27% year-over-year to $370.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $370.9 million (up 7.27% YoY) and the FY2025 annual result came in at $361.4 million, up 3.06% from the prior year.
• Total Non-Current Liabilities was $370.9 million for Q1 2026 at Xeris Biopharma Holdings, up from $361.4 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $370.9 million in Q1 2026 and bottomed at $214.5 million in Q2 2022.
• A 5-year average of $317.4 million and a median of $339.7 million in 2024 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities jumped 87.88% — and 2025, when it decreased 1.36%.
• Xeris Biopharma Holdings' Total Non-Current Liabilities stood at $273.6 million in 2022, then increased by 18.6% to $324.5 million in 2023, then rose by 8.06% to $350.7 million in 2024, then increased by 3.06% to $361.4 million in 2025, then rose by 2.61% to $370.9 million in 2026.
• Business Quant data shows XERS's Total Non-Current Liabilities at $370.9 million in Q1 2026, $361.4 million in Q4 2025, and $367.7 million in Q3 2025.